Results of the randomized phase III trial of trabectedin (F) versus doxorubicin-based chemotherapy (DXCT) as First-line therapy in patients (pts) with translocation-related sarcoma (TRS).

被引：0
|
作者：
Hendifar, Andrew Eugene
Chawla, Sant P.
Leahy, Michael Gordon
Italiano, Antoine
Patel, Shreyaskumar
Santoro, Armando
Staddon, Arthur P.
Penel, Nicolas
Piperno-Neumann, Sophie
Demetri, George D.
Hayward, Larry
White, Jeff
Gouw, Launce G.
De Miguel, Bernardo
Lardelli, Pilar
Soto, Arturo
Nieto, Antonio
Blay, Jean-Yves
机构：
[1] Sarcoma Oncol Ctr, Santa Monica, CA USA
[2] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[3] Inst Bergonie, Bordeaux, France
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Humanitas Canc Ctr, Rozzano, Italy
[6] Penn Hosp, Philadelphia, PA 19107 USA
[7] Ctr Oscar Lambert, Lille, France
[8] Inst Curie, Paris, France
[9] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[10] Western Gen Hosp, Edinburgh Canc Res UK Ctr, Edinburgh EH4 2XU, Midlothian, Scotland
[11] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[13] PharmaMar, Madrid, Spain
[14] Univ Lyon 1, Ctr Leon Berard, F-69365 Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10517
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety of trabectedin versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients with translocation-related sarcoma (TRS)
    Chawla, S. P.
    Italiano, A.
    Patel, S.
    Hohenberger, P.
    Santoro, A.
    Staddon, A. P.
    Lardelli, P.
    Gomez, J.
    Kahatt, C.
    Blay, J. Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S885 - S885
  • [2] Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS).
    Blay, Jean-Yves
    Leahy, Michael Gordon
    Binh Bui Nguyen
    Patel, Shreyaskumar
    Santoro, Armando
    Hohenberger, Peter
    Demetri, George D.
    Lardelli, Pilar
    Perez, Iratxe
    Chawla, Sant P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
    Blay, Jean-Yves
    Leahy, Michael G.
    Binh Bui Nguyen
    Patel, Shreyaskumar R.
    Hohenberger, Peter
    Santoro, Armando
    Staddon, Arthur P.
    Penel, Nicolas
    Piperno-Neumann, Sophie
    Hendifar, Andrew
    Lardelli, Pilar
    Nieto, Antonio
    Alfaro, Vicente
    Chawla, Sant P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (06) : 1137 - 1147
  • [4] Results of a multivariate analysis for potential factors affecting outcome in translocation related sarcomas (TRS) treated with trabectedin or doxorubicin-based chemotherapy (DXCT) as first-line therapy
    Chawla, S. P.
    Leahy, M. G.
    Italiano, A.
    Patel, S.
    Penel, N.
    Piperno-Neumann, S.
    Lardelli, P.
    Soto-Matos, A.
    Nieto, A.
    Blay, J. Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S885 - S885
  • [5] BRCA1 expression exploratory analysis in patients of the phase III trial of trabectedin vs. doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
    Aracil, M.
    Lardelli, P.
    Nieto, A.
    Galmarini, C. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 17 - 17
  • [6] Final results of a randomized phase II study comparing trabectedin and best supportive care (BSC) in patients (pts) with translocation-related sarcomas (TRS)
    Kunisada, T.
    Takahashi, S.
    Araki, N.
    Sugiura, H.
    Ueda, T.
    Yonemoto, T.
    Takahashi, M.
    Morioka, H.
    Hiraga, H.
    Hiruma, T.
    Matsumine, A.
    Kawai, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S704 - S704
  • [7] A randomized phase II study comparing trabectedin (T) and best supportive care (BSC) in patients (pts) with translocation-related sarcomas (TRS).
    Takahashi, Shunji
    Araki, Nobuhito
    Sugiura, Hideshi
    Ueda, Takafumi
    Takahashi, Mitsuru
    Morioka, Hideo
    Yonemoto, Tsukasa
    Hiraga, Hiroaki
    Hiruma, Toru
    Kunisada, Toshiyuki
    Matsumine, Akihiko
    Kawai, Akira
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial
    Nabholtz, JM
    Falkson, C
    Campos, D
    Szanto, J
    Martin, M
    Chan, S
    Pienkowski, T
    Zaluski, J
    Pinter, T
    Krzakowski, M
    Vorobiof, D
    Leonard, R
    Kennedy, I
    Azli, N
    Murawsky, M
    Riva, A
    Pouillart, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 968 - 975
  • [9] Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial
    Jassem, J
    Pienkowski, T
    Pluzanska, A
    Jelic, S
    Gorbunova, V
    Mrsic-Krmpotic, Z
    Berzins, J
    Nagykalnai, T
    Wigler, N
    Renard, J
    Munier, S
    Weil, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1707 - 1715
  • [10] Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study
    Kawai, Akira
    Araki, Nobuhito
    Sugiura, Hideshi
    Ueda, Takafumi
    Yonemoto, Tsukasa
    Takahashi, Mitsuru
    Morioka, Hideo
    Hiraga, Hiroaki
    Hiruma, Toru
    Kunisada, Toshiyuki
    Matsumine, Akihiko
    Tanase, Takanori
    Hasegawa, Tadashi
    Takahashi, Shunji
    [J]. LANCET ONCOLOGY, 2015, 16 (04): : 406 - 416
12345